文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

氯法齐明改善耐多药结核病临床结局:一项随机对照试验

Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial.
PubMed 文献 · Clin Microbiol Infect · 2018-07-21

在中国17家结核病专科医院开展的随机多中心研究,2009年9月至2011年9月纳入耐多药结核病患者,比较标准方案加用氯法齐明100 mg/日与单用标准方案的疗效。氯法齐明组有利结局率为65.1%,对照组为47.3%,差异有统计学意义(p 0.034,相对风险0.661,95% CI 0.243-0.949)。结论认为加用氯法齐明可改善耐多药结核病治疗。

要点

  • 标准方案加用氯法齐明100 mg/日可提高耐多药结核病有利结局率。
  • 氯法齐明组有利结局率65.1%,对照组47.3%,差异有统计学意义(p 0.034)。
  • 相对风险0.661(95% CI 0.243-0.949),支持加用氯法齐明。

核心结论

  • 在标准方案中加入氯法齐明可改善耐多药结核病的治疗。

研究设计与样本

  • 在中国17家结核病专科医院开展的随机多中心研究,2009年9月至2011年9月纳入耐多药结核病患者。
  • 筛查156例,对照组74例,氯法齐明组66例;干预组在标准方案基础上加用氯法齐明100 mg/日。
  • 主要结局为治疗成功患者的比例。

主要发现

  • 氯法齐明组66例中36例治愈、7例完成治疗,有利结局率为65.1%。
  • 对照组有利结局率为47.3%(35/74),显著低于氯法齐明组(p 0.034)。
  • 相对风险0.661(95% CI 0.243-0.949)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We carried out a randomized multicentre study in China to investigate whether the clofazimine would improve the efficacy of the standardized regimen in patients with multidrug-resistant tuberculosis (MDR-TB). METHODS: Patients with MDR-TB managed in 17 TB specialist hospitals in China between September 2009 and September 2011 were randomly assigned to the treatment groups at enrolment. In the intervention group, 100 mg clofazimine per day was added to the standardized regimen. The primary outcome was the proportion of patients with successful outcomes. RESULTS: From the 156 patients that were screened, 74 were assigned to the control group and 66 to the clofazimine group. Of the 66 cases analysed for clinical outcome in the clofazimine group, 36 patients were cured, and seven completed treatment, yielding a favourable outcome rate of 65.1%. The proportion of patients with favourable outcomes receiving the control regimen was 47.3% (35/74), which was significantly lower than that in the clofazimine group (p 0.034, relative risk 0.661, 95% CI 0.243-0.949). CONCLUSIONS: The addition of clofazimine to the standard regimen improved the treatment of MDR-TB.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Duan H, Chen X, Li Z, et al. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial. Clin Microbiol Infect. 2018. PMID: 30036672. doi:10.1016/j.cmi.2018.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。